Molecular mechanisms and targeting of colorectal cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Metastatic colorectal cancer (mCRC) treatment has advanced with targeted therapies.
• Current targeted agents focus on two main pathways: vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).

Purpose of the Study:

• To review approved targeted therapies for mCRC.
• To categorize therapies based on their molecular targets (VEGF or EGFR).
• To discuss the efficacy of these agents in combination settings and future therapeutic directions.

Main Methods:

• Literature review of approved targeted therapies for mCRC.
• Classification of therapies based on their mechanism of action (VEGF ligand/receptor inhibition, EGFR inhibition).
• Summary of clinical efficacy in first-line and combination settings.

Main Results:

• Targeted therapies for mCRC are grouped into anti-VEGF and anti-EGFR agents.
• Anti-VEGF therapies include ligand inhibitors (e.g., bevacizumab) and receptor inhibitors (e.g., PTK/ZK).
• Anti-EGFR therapies include monoclonal antibodies (e.g., cetuximab) and tyrosine kinase inhibitors (e.g., gefitinib).
• Both VEGF and EGFR-targeted therapies demonstrate efficacy in first-line and combination treatments.

Conclusions:

• VEGF and EGFR targeted therapies are crucial in managing metastatic colorectal cancer.
• Combination strategies and gene profiling are promising future directions for mCRC treatment.
• Future research may involve combining chemotherapy (capecitabine, oxaliplatin) with targeted agents like bevacizumab and cetuximab.